GLUE
Price
$4.05
Change
+$0.04 (+1.00%)
Updated
May 22 closing price
Capitalization
249.11M
76 days until earnings call
GUTS
Price
$1.75
Change
-$0.09 (-4.89%)
Updated
May 22 closing price
Capitalization
85.95M
82 days until earnings call
Interact to see
Advertisement

GLUE vs GUTS

Header iconGLUE vs GUTS Comparison
Open Charts GLUE vs GUTSBanner chart's image
Monte Rosa Therapeutics
Price$4.05
Change+$0.04 (+1.00%)
Volume$320.33K
Capitalization249.11M
Fractyl Health
Price$1.75
Change-$0.09 (-4.89%)
Volume$108.74K
Capitalization85.95M
GLUE vs GUTS Comparison Chart
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GUTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. GUTS commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Buy and GUTS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (GLUE: $4.05 vs. GUTS: $1.75)
Brand notoriety: GLUE and GUTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 45% vs. GUTS: 42%
Market capitalization -- GLUE: $249.11M vs. GUTS: $85.95M
GLUE [@Biotechnology] is valued at $249.11M. GUTS’s [@Biotechnology] market capitalization is $85.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 0 FA rating(s) are green whileGUTS’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 0 green, 5 red.
  • GUTS’s FA Score: 0 green, 5 red.
According to our system of comparison, GUTS is a better buy in the long-term than GLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 5 TA indicator(s) are bullish while GUTS’s TA Score has 5 bullish TA indicator(s).

  • GLUE’s TA Score: 5 bullish, 3 bearish.
  • GUTS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than GUTS.

Price Growth

GLUE (@Biotechnology) experienced а +4.65% price change this week, while GUTS (@Biotechnology) price change was +6.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.00%. For the same industry, the average monthly price growth was +5.57%, and the average quarterly price growth was -1.69%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

GUTS is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+3.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($249M) has a higher market cap than GUTS($86M). GUTS YTD gains are higher at: -14.806 vs. GLUE (-41.643). GLUE has higher annual earnings (EBITDA): 6.14M vs. GUTS (-92.85M). GLUE has more cash in the bank: 326M vs. GUTS (67.5M). GLUE has less debt than GUTS: GLUE (41.9M) vs GUTS (62.5M). GLUE has higher revenues than GUTS: GLUE (159M) vs GUTS (93K).
GLUEGUTSGLUE / GUTS
Capitalization249M86M290%
EBITDA6.14M-92.85M-7%
Gain YTD-41.643-14.806281%
P/E Ratio33.75N/A-
Revenue159M93K170,968%
Total Cash326M67.5M483%
Total Debt41.9M62.5M67%
TECHNICAL ANALYSIS
Technical Analysis
GLUEGUTS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GUTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGWCX32.14N/A
N/A
Virtus Silvant Focused Growth C
DEMZX22.63N/A
N/A
Macquarie Emerging Markets R6
CAPTX11.11N/A
N/A
Canterbury Portfolio Thermostat I
NUESX20.85N/A
N/A
Northern US Quality ESG K
DAINX19.11N/A
N/A
Dunham International Stock A

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+1.00%
EYPT - GLUE
48%
Loosely correlated
-4.60%
ATXS - GLUE
42%
Loosely correlated
N/A
IMNM - GLUE
42%
Loosely correlated
+6.82%
CRSP - GLUE
42%
Loosely correlated
+1.46%
RXRX - GLUE
41%
Loosely correlated
N/A
More

GUTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GUTS has been loosely correlated with CABA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GUTS jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GUTS
1D Price
Change %
GUTS100%
-4.62%
CABA - GUTS
36%
Loosely correlated
-0.84%
YMAB - GUTS
36%
Loosely correlated
N/A
IPSC - GUTS
35%
Loosely correlated
-0.93%
AKBA - GUTS
35%
Loosely correlated
+0.71%
GLUE - GUTS
35%
Loosely correlated
+1.00%
More